An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms

Area of Science:

• Oncology
• Biochemistry
• Drug Discovery

Background:

• Atypical Protein Kinase C (PKC) enzymes are validated targets for cancer therapy.
• Targeted cancer therapies, including small molecule kinase inhibitors, are crucial for personalized medicine.
• Allosteric drug development offers innovative therapeutic potential but presents significant challenges.

Purpose of the Study:

• To develop a new class of allosteric inhibitors targeting atypical PKCs.
• To characterize the mechanism of inhibition and efficacy of these novel compounds.
• To explore the potential of these compounds as future cancer therapeutics.

Main Methods:

• Development of novel compounds targeting the PIF-pocket of atypical PKCs.
• Biochemical assays to assess allosteric inhibition of kinase activity.
• Crystallographic studies to determine compound-protein interactions.
• In vitro proliferation assays using non-small cell lung cancer cells.
• In vivo efficacy studies in a mouse xenograft model.

Main Results:

• A new class of allosteric inhibitors targeting the PIF-pocket of atypical PKCs was successfully developed.
• Biochemical and crystallographic data confirmed allosteric inhibition of atypical PKC activity.
• The representative compound PS432 demonstrated potent inhibition of non-small cell lung cancer cell proliferation.
• PS432 significantly reduced tumor growth in a mouse xenograft model with no observed side effects.
• The developed compounds are druglike and allow for synthesis of derivatives.

Conclusions:

• Novel allosteric inhibitors targeting atypical PKCs have been developed.
• These compounds represent a promising new class of targeted cancer therapeutics.
• The druglike nature of these compounds facilitates further optimization for clinical application.